Tangram submits application to MHRA for TGM-312 Phase I/II clinical trial
Tangram Therapeutics has submitted a clinical trial application (CTA) to the Medicines and Healthcare products Regulatory Agency (MHRA) to begin a Phase I/II trial of TGM-312.
TGM-312 is an investigational GalOmic small interfering RNA (siRNA) that aims to silence a gene in hepatocytes as a treatment fir metabolic dysfunction-associated steatohepatitis (MASH).
The proposed Phase I/II study will ****** s TGM-312 in healthy adult individuals and MASH patients, focusing on the pharmacodynamics, tolerability, safety, an
Tangram Therapeutics has submitted a clinical trial application (CTA) to the Medicines and Healthcare products Regulatory Agency (MHRA) to begin a Phase I/II trial of TGM-312.
TGM-312 is an investigational GalOmic small interfering RNA (siRNA) that aims to silence a gene in hepatocytes as a treatment fir metabolic dysfunction-associated steatohepatitis (MASH).
The proposed Phase I/II study will ****** s TGM-312 in healthy adult individuals and MASH patients, focusing on the pharmacodynamics, tolerability, safety, an
9 months ago
